SG11201607623XA - Preparation containing tetracyclic compound at high dose - Google Patents
Preparation containing tetracyclic compound at high doseInfo
- Publication number
- SG11201607623XA SG11201607623XA SG11201607623XA SG11201607623XA SG11201607623XA SG 11201607623X A SG11201607623X A SG 11201607623XA SG 11201607623X A SG11201607623X A SG 11201607623XA SG 11201607623X A SG11201607623X A SG 11201607623XA SG 11201607623X A SG11201607623X A SG 11201607623XA
- Authority
- SG
- Singapore
- Prior art keywords
- high dose
- preparation containing
- tetracyclic compound
- containing tetracyclic
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014092101 | 2014-04-25 | ||
PCT/JP2015/062520 WO2015163448A1 (en) | 2014-04-25 | 2015-04-24 | Preparation containing tetracyclic compound at high dose |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201607623XA true SG11201607623XA (en) | 2016-11-29 |
Family
ID=54332608
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202009484WA SG10202009484WA (en) | 2014-04-25 | 2015-04-24 | Preparation containing tetracyclic compound at high dose |
SG11201607623XA SG11201607623XA (en) | 2014-04-25 | 2015-04-24 | Preparation containing tetracyclic compound at high dose |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202009484WA SG10202009484WA (en) | 2014-04-25 | 2015-04-24 | Preparation containing tetracyclic compound at high dose |
Country Status (17)
Country | Link |
---|---|
US (4) | US10350214B2 (en) |
EP (1) | EP3135287A4 (en) |
JP (2) | JP5859712B1 (en) |
KR (2) | KR102412321B1 (en) |
CN (2) | CN106456651A (en) |
AR (1) | AR100187A1 (en) |
AU (2) | AU2015250574B2 (en) |
BR (1) | BR112016021206B1 (en) |
CA (2) | CA3140565C (en) |
IL (2) | IL248363B (en) |
MX (2) | MX2016013809A (en) |
MY (1) | MY189913A (en) |
RU (2) | RU2020119391A (en) |
SG (2) | SG10202009484WA (en) |
TW (2) | TWI720943B (en) |
WO (1) | WO2015163448A1 (en) |
ZA (1) | ZA201606447B (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2764653C (en) * | 2009-06-10 | 2018-01-02 | Chugai Seiyaku Kabushiki Kaisha | Tetracyclic compounds |
EP2606886B1 (en) | 2010-08-20 | 2020-01-08 | Chugai Seiyaku Kabushiki Kaisha | Composition comprising tetracyclic compound |
CA3077553C (en) | 2012-09-25 | 2022-08-02 | Chugai Seiyaku Kabushiki Kaisha | Ret inhibitor |
PL3023100T3 (en) | 2013-07-18 | 2019-07-31 | Taiho Pharmaceutical Co., Ltd. | Antitumor drug for intermittent administration of fgfr inhibitor |
US10124003B2 (en) | 2013-07-18 | 2018-11-13 | Taiho Pharmaceutical Co., Ltd. | Therapeutic agent for FGFR inhibitor-resistant cancer |
AU2015250574B2 (en) | 2014-04-25 | 2020-07-16 | Chugai Seiyaku Kabushiki Kaisha | Preparation containing tetracyclic compound at high dose |
TWI718102B (en) | 2014-08-08 | 2021-02-11 | 日商中外製藥股份有限公司 | Amorphous body of tetracyclic compound |
US11077093B2 (en) | 2015-01-16 | 2021-08-03 | Chugai Seiyaku Kabushiki Kaisha | Combination drug |
CN111393446B (en) | 2015-03-31 | 2022-12-20 | 大鹏药品工业株式会社 | 3, 5-disubstituted phenylalkynyl compound crystal |
US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
KR20190137920A (en) * | 2017-04-28 | 2019-12-11 | 아스텔라스세이야쿠 가부시키가이샤 | Pharmaceutical composition for oral administration containing enzalutamide |
CA3094431C (en) | 2018-03-19 | 2023-06-27 | Taiho Pharmaceutical Co., Ltd. | Pharmaceutical composition including sodium alkyl sulfate |
WO2020004630A1 (en) * | 2018-06-29 | 2020-01-02 | 中外製薬株式会社 | Pharmaceutical composition containing poorly-soluble basic medicine |
AR116113A1 (en) | 2018-09-04 | 2021-03-31 | Chugai Pharmaceutical Co Ltd | METHOD FOR MANUFACTURING A TETRACYCLIC COMPOUND |
AR121187A1 (en) | 2019-12-27 | 2022-04-27 | Chugai Pharmaceutical Co Ltd | METHOD TO CLASSIFY, EVALUATE OR MANUFACTURE SODIUM LAURYL SULFATE FROM RAW MATERIAL OR PHARMACEUTICAL FORMULATION CONTAINING IT |
CN112218626B (en) * | 2019-12-31 | 2023-03-24 | 广州帝奇医药技术有限公司 | Sustained release composition and preparation method thereof |
JP7419572B2 (en) | 2021-01-29 | 2024-01-22 | 中外製薬株式会社 | Pharmaceutical composition for childhood cancer treatment |
WO2023074785A1 (en) * | 2021-10-28 | 2023-05-04 | 中外製薬株式会社 | Syrup preparation |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4918630B1 (en) | 1970-07-29 | 1974-05-11 | ||
US5028433A (en) | 1988-11-30 | 1991-07-02 | Banyu Pharmaceutical Co., Ltd. | Readily absorbable drug formulation of NB-818 |
JPH0667840B2 (en) | 1988-11-30 | 1994-08-31 | 萬有製薬株式会社 | NB-818 easily absorbable formulation |
JPH0892090A (en) | 1994-07-26 | 1996-04-09 | Tanabe Seiyaku Co Ltd | Medicinal composition |
DE69505470T2 (en) | 1994-08-04 | 1999-05-12 | Hoffmann La Roche | Pyrrolocarbazole |
JPH09202728A (en) | 1995-12-11 | 1997-08-05 | Hisamitsu Pharmaceut Co Inc | Solid preparation |
WO1997041127A1 (en) | 1996-05-01 | 1997-11-06 | Eli Lilly And Company | Halo-substituted protein kinase c inhibitors |
CA2372032A1 (en) | 1999-05-14 | 2000-11-23 | Rodney W. Rickards | Compounds and therapeutic methods |
US7125565B2 (en) | 2000-12-01 | 2006-10-24 | Kyowa Hakko Kogyo Co., Ltd. | Composition improved in the solubility or oral absorbability |
GB0030417D0 (en) | 2000-12-13 | 2001-01-24 | Pharma Mar Sa | An anticancer lead compound isolated from a New Zealand ascidian |
FR2841138B1 (en) | 2002-06-25 | 2005-02-25 | Cll Pharma | SOLID PHARMACEUTICAL COMPOSITION COMPRISING A LIPOPHILIC ACTIVE INGREDIENT, ITS PREPARATION PROCESS |
US7807197B2 (en) | 2002-09-28 | 2010-10-05 | Mcneil-Ppc, Inc. | Composite dosage forms having an inlaid portion |
JP2007501857A (en) | 2003-02-28 | 2007-02-01 | イノテック ファーマシューティカルズ コーポレーション | Tetracyclic benzamide derivatives and methods of use thereof |
DK1454992T3 (en) | 2003-03-07 | 2006-10-02 | Ist Naz Stud Cura Dei Tumori | Anaplastic lymphoma kinase assay, reagents and compositions thereof |
GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
CA2532800C (en) | 2003-07-23 | 2013-06-18 | Exelixis, Inc. | Anaplastic lymphoma kinase modulators and methods of use |
US7378414B2 (en) | 2003-08-25 | 2008-05-27 | Abbott Laboratories | Anti-infective agents |
US20070060595A1 (en) | 2003-10-10 | 2007-03-15 | Toshio Yoshizawa | Novel fused heterocyclic compound and use thereof |
CN1902200A (en) | 2003-11-21 | 2007-01-24 | 诺瓦提斯公司 | 1h-imidazoquinoline derivatives as protein kinase inhibitors |
WO2005056529A1 (en) | 2003-12-12 | 2005-06-23 | Merck Frosst Canada Ltd. | Cathepsin cysteine protease inhibitors |
CN1934082A (en) | 2004-03-19 | 2007-03-21 | 斯皮德尔实验股份公司 | Organic compounds |
WO2005097765A1 (en) | 2004-03-31 | 2005-10-20 | Exelixis, Inc. | Anaplastic lymphoma kinase modulators and methods of use |
ATE463486T1 (en) | 2004-08-26 | 2010-04-15 | Pfizer | ENANTIOMER PURE AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS |
US7091202B2 (en) | 2004-09-15 | 2006-08-15 | Bristol-Myers Squibb Company | 4-arylspirocycloalkyl-2-aminopyrimidine carboxamide KCNQ potassium channel modulators |
GB0517329D0 (en) | 2005-08-25 | 2005-10-05 | Merck Sharp & Dohme | Stimulation of neurogenesis |
US20080292608A1 (en) | 2005-11-07 | 2008-11-27 | Irm Llc | Compounds and Compositions as Ppar Modulators |
AU2006323025B2 (en) | 2005-12-05 | 2012-07-05 | Pfizer Products Inc. | Polymorphs of a c-Met/HGFR inhibitor |
US7601716B2 (en) | 2006-05-01 | 2009-10-13 | Cephalon, Inc. | Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors |
US8063225B2 (en) | 2006-08-14 | 2011-11-22 | Chembridge Corporation | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders |
US20080085309A1 (en) * | 2006-09-14 | 2008-04-10 | Astellas Pharma Inc. | Rapidly disintegrating tablets in buccal cavity and manufacturing method thereof |
CA2598893C (en) | 2006-10-11 | 2012-04-10 | Astellas Pharma Inc. | Eml4-alk fusion gene |
EP1914240B1 (en) | 2006-10-11 | 2009-12-02 | Astellas Pharma Inc. | EML4-ALK fusion gene |
TWI432427B (en) | 2006-10-23 | 2014-04-01 | Cephalon Inc | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors |
US8546394B2 (en) | 2007-04-17 | 2013-10-01 | Bristol-Myers Squibb Company | Substituted [1,2,4]triazolo[4,3-A]pyrazine 11-beta-hydroxysteroid dehydrogenase inhibitors |
TWI389893B (en) | 2007-07-06 | 2013-03-21 | Astellas Pharma Inc | Di (arylamino) ary1 compound |
CN103923072B (en) | 2007-07-20 | 2017-05-31 | 内尔维阿诺医学科学有限公司 | As the substituted indazole derivative with kinase inhibitory activity |
WO2009073620A2 (en) | 2007-11-30 | 2009-06-11 | Newlink Genetics | Ido inhibitors |
US20090214648A1 (en) * | 2008-02-15 | 2009-08-27 | Malathi Kandakatla | Pharmaceutical formulations comprising ibuprofen and diphenhydramine |
WO2009113420A1 (en) | 2008-03-13 | 2009-09-17 | 第一三共株式会社 | Improvement of dissolvability of preparation containing olmesartan medoxomil |
WO2010038688A1 (en) * | 2008-09-30 | 2010-04-08 | アステラス製薬株式会社 | Particulate pharmaceutical composition for oral administration of atorvastatin |
CN102574830A (en) | 2009-05-07 | 2012-07-11 | 阿斯利康(瑞典)有限公司 | Substituted 1-cyanoethylheterocyclylcarboxamide compounds 750 |
CA2764653C (en) * | 2009-06-10 | 2018-01-02 | Chugai Seiyaku Kabushiki Kaisha | Tetracyclic compounds |
GB0910046D0 (en) | 2009-06-10 | 2009-07-22 | Glaxosmithkline Biolog Sa | Novel compositions |
US8609097B2 (en) | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
US20110311625A1 (en) * | 2010-06-14 | 2011-12-22 | Amruth Gowda Doddaveerappa | Solid dosage forms of fenofibrate |
EP2606886B1 (en) | 2010-08-20 | 2020-01-08 | Chugai Seiyaku Kabushiki Kaisha | Composition comprising tetracyclic compound |
TWI564008B (en) | 2010-09-30 | 2017-01-01 | 鹽野義製藥股份有限公司 | Formulation for solubility enhancement of poorly soluble drugs |
JP5006987B2 (en) | 2010-11-22 | 2012-08-22 | 中外製薬株式会社 | Medicine containing tetracyclic compound |
JP5977331B2 (en) * | 2011-04-06 | 2016-08-24 | ダウ グローバル テクノロジーズ エルエルシー | Method for producing cellulose derivative having high bulk density and good fluidity |
CA2869145A1 (en) * | 2012-04-04 | 2013-10-10 | IVAX International GmbH | Pharmaceutical compositions for combination therapy |
CA3077553C (en) | 2012-09-25 | 2022-08-02 | Chugai Seiyaku Kabushiki Kaisha | Ret inhibitor |
US9381246B2 (en) * | 2013-09-09 | 2016-07-05 | Triact Therapeutics, Inc. | Cancer therapy |
CA2946268A1 (en) | 2014-04-25 | 2015-10-29 | Chugai Seiyaku Kabushiki Kaisha | Crystal of tetracyclic compound |
AU2015250574B2 (en) | 2014-04-25 | 2020-07-16 | Chugai Seiyaku Kabushiki Kaisha | Preparation containing tetracyclic compound at high dose |
KR102379639B1 (en) | 2014-06-18 | 2022-03-28 | 에프. 호프만-라 로슈 아게 | New pharmaceutical composition comprising non-ionic surfactants |
TWI718102B (en) | 2014-08-08 | 2021-02-11 | 日商中外製藥股份有限公司 | Amorphous body of tetracyclic compound |
-
2015
- 2015-04-24 AU AU2015250574A patent/AU2015250574B2/en active Active
- 2015-04-24 WO PCT/JP2015/062520 patent/WO2015163448A1/en active Application Filing
- 2015-04-24 KR KR1020167031396A patent/KR102412321B1/en active IP Right Grant
- 2015-04-24 SG SG10202009484WA patent/SG10202009484WA/en unknown
- 2015-04-24 BR BR112016021206-1A patent/BR112016021206B1/en active IP Right Grant
- 2015-04-24 CN CN201580020724.5A patent/CN106456651A/en active Pending
- 2015-04-24 EP EP15783124.9A patent/EP3135287A4/en active Pending
- 2015-04-24 MX MX2016013809A patent/MX2016013809A/en unknown
- 2015-04-24 US US15/304,133 patent/US10350214B2/en active Active
- 2015-04-24 CA CA3140565A patent/CA3140565C/en active Active
- 2015-04-24 MY MYPI2016001752A patent/MY189913A/en unknown
- 2015-04-24 JP JP2015530792A patent/JP5859712B1/en active Active
- 2015-04-24 CN CN202111292754.5A patent/CN113975243A/en active Pending
- 2015-04-24 SG SG11201607623XA patent/SG11201607623XA/en unknown
- 2015-04-24 CA CA2946518A patent/CA2946518C/en active Active
- 2015-04-24 KR KR1020227020701A patent/KR102478887B1/en active IP Right Grant
- 2015-04-24 TW TW104113204A patent/TWI720943B/en active
- 2015-04-24 RU RU2020119391A patent/RU2020119391A/en unknown
- 2015-04-24 AR ARP150101248A patent/AR100187A1/en unknown
- 2015-04-24 TW TW109145714A patent/TWI771839B/en active
- 2015-04-24 RU RU2016145057A patent/RU2724056C2/en active
- 2015-12-16 JP JP2015244821A patent/JP6129942B2/en active Active
-
2016
- 2016-09-19 ZA ZA2016/06447A patent/ZA201606447B/en unknown
- 2016-10-13 IL IL248363A patent/IL248363B/en active IP Right Grant
- 2016-10-20 MX MX2021012300A patent/MX2021012300A/en unknown
-
2019
- 2019-07-11 US US16/508,760 patent/US11433076B2/en active Active
-
2020
- 2020-09-10 AU AU2020230293A patent/AU2020230293B2/en active Active
-
2021
- 2021-05-12 IL IL283152A patent/IL283152B2/en unknown
-
2022
- 2022-07-29 US US17/877,542 patent/US20220378800A1/en not_active Abandoned
- 2022-08-26 US US17/896,758 patent/US20230105990A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201606447B (en) | Preparation containing tetracyclic compound at high dose | |
IL249181A0 (en) | Compound containing self-immolative group | |
GB201419579D0 (en) | Pharmaceutical compound | |
GB201414730D0 (en) | Pharmaceutical compound | |
GB201509443D0 (en) | Seed preparation | |
GB201402277D0 (en) | Pharmaceutical compounds | |
IL246447A0 (en) | Pharmaceutical preparation containing pyridylaminoacetic acid compound | |
GB201415569D0 (en) | Therapeutic Compounds | |
HK1256671A1 (en) | Spirocyclic compounds | |
HUE039338T2 (en) | Scintillator | |
GB201416273D0 (en) | Therapeutic compounds | |
HK1232121A1 (en) | Fullerene compounds as antioxidant therapy | |
SG11201702334SA (en) | External preparation composition containing s-flurbiprofen | |
IL249907A0 (en) | Tricyclic triazolic compounds | |
ZA201500995B (en) | Low dose pharmaceutical composition | |
HK1254378A1 (en) | [(2-ethoxy-5-trans-1-propen-1-yl)-phenoxyl]-terminated compounds | |
ZA201800217B (en) | Novel dosage regimen tiacumicin compound | |
HK1219664A1 (en) | Dosage form containing fungal components | |
GB201520189D0 (en) | Compound for use | |
GB201419570D0 (en) | Pharmaceutical compound | |
GB201411215D0 (en) | Pharmaceutical compound | |
GB201416462D0 (en) | Compound for use | |
GB201409405D0 (en) | Therapeutic compounds | |
GB201406154D0 (en) | Pharmaceutical compound | |
GB201407122D0 (en) | Therapeutic compounds |